DDInter908 DDInter899
Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Iloprost {u} (Compound) resembles {v} (Compound) Bimatoprost
Iloprost {u} (Compound) binds {v} (Gene) PDE4D
Iloprost {u} (Compound) is included by {v} (Pharmacologic Class) Prostaglandins I
Iloprost {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Iloprost {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tadalafil
Iloprost {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trandolapril
Iloprost {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimethaphan
Iloprost {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Iloprost {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Iloprost (Compound) resembles Bimatoprost (Compound)
Iloprost (Compound) binds PDE4D (Gene)
Iloprost (Compound) is included by Prostaglandins I (Pharmacologic Class)
Iloprost may cause a minor interaction that can limit clinical effects when taken with Capsicum
Iloprost may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Iloprost may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan